Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
9007-72-1
Molecular formula
Not available
Molecular weight
~150000 g/mol
Drug class
Intravenous iron(III)-carbohydrate complexparenteral iron replacement agent
Mechanism of action
A stable colloidal iron(III)-hydroxide complex with carboxymaltose carbohydrate. Following intravenous administration, iron is taken up by reticuloendothelial cells and made available for transferrin binding and incorporation into haemoglobin and iron stores; it is not a simple dissociating iron salt.
Indications / reported uses
Treatment of iron-deficiency anaemia in adults and eligible paediatric patients when oral iron is ineffective, not tolerated or rapid iron replacement is needed
Treatment of iron deficiency in selected patients with heart failure where the specific formulation is authorised; use and dosing are product-label specific
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Ferric Carboxymaltose Environmental Risk Assessment (ERA) (the Ferric Carboxymaltose ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.